Enhabit, Inc. (NYSE:EHAB - Get Free Report) Director Stuart M. Mcguigan purchased 15,000 shares of Enhabit stock in a transaction dated Tuesday, December 10th. The shares were purchased at an average price of $8.81 per share, with a total value of $132,150.00. Following the completion of the transaction, the director now directly owns 46,810 shares in the company, valued at approximately $412,396.10. This represents a 47.15 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link.
Enhabit Price Performance
Shares of Enhabit stock opened at $8.53 on Thursday. The business's 50-day moving average price is $7.52 and its 200-day moving average price is $8.31. The firm has a market capitalization of $428.92 million, a PE ratio of -3.68 and a beta of 1.89. Enhabit, Inc. has a 12 month low of $6.85 and a 12 month high of $11.74. The company has a current ratio of 1.46, a quick ratio of 1.46 and a debt-to-equity ratio of 0.85.
Enhabit (NYSE:EHAB - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.01). The business had revenue of $253.60 million for the quarter, compared to analysts' expectations of $261.69 million. Enhabit had a positive return on equity of 1.67% and a negative net margin of 11.24%. During the same period last year, the business posted $0.03 earnings per share. Sell-side analysts forecast that Enhabit, Inc. will post 0.22 EPS for the current fiscal year.
Institutional Trading of Enhabit
Amazon coin set to soar 25X – starting December 16th?
From True Market Insiders | Ad
This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon.
And one team of crypto experts has identified it as the most promising crypto of 2024.
You can see all of the details surrounding the #1 Crypto of 2024
>3-Cent Amazon Coin<
Several hedge funds have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD increased its position in shares of Enhabit by 5.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 37,950 shares of the company's stock valued at $443,000 after acquiring an additional 2,078 shares during the period. Gladius Capital Management LP bought a new position in Enhabit during the 2nd quarter valued at approximately $31,000. SummerHaven Investment Management LLC lifted its holdings in Enhabit by 2.8% in the 2nd quarter. SummerHaven Investment Management LLC now owns 61,508 shares of the company's stock worth $549,000 after buying an additional 1,660 shares during the period. Bank of New York Mellon Corp boosted its holdings in Enhabit by 1.5% in the second quarter. Bank of New York Mellon Corp now owns 400,575 shares of the company's stock valued at $3,573,000 after acquiring an additional 5,936 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its position in shares of Enhabit by 1,119.6% during the second quarter. Allspring Global Investments Holdings LLC now owns 45,832 shares of the company's stock valued at $409,000 after buying an additional 42,074 shares during the period.
Wall Street Analysts Forecast Growth
Several equities analysts recently commented on the company. Jefferies Financial Group upgraded Enhabit from a "hold" rating to a "buy" rating and boosted their target price for the stock from $8.25 to $9.50 in a research report on Monday. Leerink Partners restated a "market perform" rating and issued a $8.00 price objective (down from $8.50) on shares of Enhabit in a research report on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, Enhabit currently has a consensus rating of "Hold" and an average target price of $9.40.
Check Out Our Latest Stock Report on EHAB
Enhabit Company Profile
(
Get Free Report)
Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
